Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Thomas K Equels is CEO & President at Aim Immunotech. OQRO lists 26 transactions filed with the SEC under this name, the latest on Nov 13, 2026, each linked to the official Form 4.
CEO & President
Disclosures on record
26
Companies involved
1
5 buys, median −40.0 pts vs S&P 500, beat it 0 of 5 times.
Average −54.5 pts vs S&P 500. Each buy is one disclosure of open-market purchases in one company on one filing date, filed Nov 20, 2024 to Jun 16, 2025, measured from the first close after the filing. Past results, not a forecast.
22 purchases disclosed; 0% of the 5 measured at 90 days finished ahead of the index. $1,000 placed after each of the 10 purchases disclosed since 2025-11-14 would be worth $8.4K today ($10K put in); the same in the S&P 500 (SPY): $9.9K.
Not ranked: fewer than 10 purchases measured at 90 days. The middle of the 82 ranked insiders is −5.5 pts (median, against the S&P 500).
Equal weight counts every purchase once; by size counts it for its disclosed dollars. Both are measured from the first close after it was reported. Past results describe the past, not a forecast. How this is measured · Leaderboard
Aim ImmunotechAIM
26 disclosures · Nov 2024 – Nov 2026 · 22 bought
Nov 11, 2026Bought~$5.2Kdisclosed Nov 13
DetailsOfficial recordNov 10, 2026Bought~$5.4Kdisclosed Nov 12
DetailsOfficial recordNov 9, 2026Bought~$5.1Kdisclosed Nov 10
DetailsOfficial recordNov 6, 2026Bought~$2Kdisclosed Nov 9
DetailsOfficial recordNov 6, 2026Bought~$3.2K
DetailsOfficial recordOct 23, 2026Bought~$5.1Kdisclosed Oct 26
DetailsOfficial recordOct 22, 2026Bought~$5.1Kdisclosed Oct 23
DetailsOfficial recordSep 17, 2026Bought~$5Kdisclosed Sep 18
DetailsOfficial recordSep 16, 2026Bought~$2.3Kdisclosed Sep 17
DetailsOfficial recordSep 15, 2026Bought~$4.9Kdisclosed Sep 16
DetailsOfficial recordSep 14, 2026Bought~$1.3Kdisclosed Sep 15
DetailsOfficial recordMar 12, 202625Kdisclosed Mar 16
DetailsOfficial recordMar 12, 202625disclosed Mar 16
DetailsOfficial recordMar 6, 202650Kdisclosed Mar 10
DetailsOfficial recordMar 6, 202625disclosed Mar 10
DetailsOfficial recordJun 13, 2025Bought~$824disclosed Jun 16
DetailsOfficial recordJun 12, 2025Bought~$896disclosed Jun 13
DetailsOfficial recordApr 11, 2025Bought~$50Kdisclosed Apr 23
DetailsOfficial recordApr 4, 2025Bought~$2.6Kdisclosed Apr 7
DetailsOfficial recordMar 5, 2025Bought~$6.7Kdisclosed Mar 6
DetailsOfficial recordMar 4, 2025Bought~$5.1Kdisclosed Mar 5
DetailsOfficial recordMar 4, 2025Bought~$10K
DetailsOfficial recordNov 21, 2024Bought~$4.2Kdisclosed Jan 21
DetailsOfficial recordDec 18, 2024Bought~$4.7Kdisclosed Dec 19
DetailsOfficial recordNov 20, 2024Bought~$17Kdisclosed Nov 21
DetailsOfficial recordNov 20, 2024Bought~$11K
DetailsOfficial recordAs of the latest filing on , Thomas K Equels reported holding 328,095 shares of Aim Immunotech (AIM), worth about $47K at the last close of $0 (Nov 13, 2026). In the last 12 months, Thomas K Equels bought $44K in 11 open-market purchases.
Aim Immunotech's proxy statement reports total compensation of $640K for Thomas K Equels for fiscal year 2025, after $1.09M for 2024. The total is the one in the Summary Compensation Table: it counts stock awards at their value on the grant date, so it is not the cash received. Proxy statement filed Sep 30, 2026
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Aim Immunotech AIM | 328,095 | 328K direct | $0 | $47K | Nov 11, 2026 |
Is this Thomas K Equels’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Thomas K Equels bought shares on the open market in 11 different years since 2015.
Thomas K Equels reported 72 open-market purchases and 0 sales since 2015; purchases in 11 different years, most recently 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $44K11×11 trades | — |
| 2025 | $76K7×7 trades | — |
| 2024 | $95K8×8 trades | — |
| 2023 | $100K6×6 trades | — |
| 2021 | $55K2×2 trades | — |
| 2020 | $75K3×3 trades | — |
| 2019 | $132K3×3 trades | — |
| 2018 | $80K13×13 trades | — |
| 2017 | $150K2×2 trades | — |
| 2016 | $95K11×11 trades | — |
| 2015 | $85K6×6 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the latest SEC Form 4, dated Nov 11, 2026, Thomas K Equels reported holding 328,095 shares of Aim Immunotech (AIM). At the last close of $0 on Nov 13, 2026, that is about $47K. This is the stake disclosed in filings, not a net worth.
In SEC filings of the last 12 months, Thomas K Equels reported 11 open-market purchases worth $44K, and no open-market sale. Shares withheld for taxes, gifts and option exercises are not counted in these totals.
Aim Immunotech's proxy statement reports total compensation of $640K for Thomas K Equels for fiscal year 2025, after $1.09M for 2024. The total is the one in the Summary Compensation Table: it counts stock awards at their value on the grant date, so it is not the cash received.
Thomas K Equels bought shares on the open market in 11 different years since 2015.
In SEC filings since 2015: the latest open-market purchase is from 2026; no open-market sale is on record.
Aim Immunotech (AIM), from 2015 to 2026: 72 purchases and 0 sales.
Thomas K Equels reported 72 open-market purchases and 0 sales here, 2015 to 2026.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
